Found 6 matching trials
Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules PHASE3 The present study will evaluate the immunogenicity, safety and immunogenici...
Show More Location
Vaccination and Travel Medicine Centre
Learn More & Join Trial
Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years PHASE1 Today, the leading contender for the next pandemic of influenza is H5N1, a ...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population PHASE2 Influenza pandemics are caused by viruses that possess an Hemagglutinin mol...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults PHASE3 The present study is designed to assess the lot-to-lot consistency of the i...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age PHASE2 The present study is designed to evaluate the immunogenicity and safety of ...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults PHASE2 The present study is designed to evaluate the reactogenicity and immunogeni...
Show More Location
GSK Investigational Site
Learn More & Join Trial